[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

GB0012997D0 - Gene delivery - Google Patents

Gene delivery

Info

Publication number
GB0012997D0
GB0012997D0 GBGB0012997.3A GB0012997A GB0012997D0 GB 0012997 D0 GB0012997 D0 GB 0012997D0 GB 0012997 A GB0012997 A GB 0012997A GB 0012997 D0 GB0012997 D0 GB 0012997D0
Authority
GB
United Kingdom
Prior art keywords
gene delivery
gene
delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0012997.3A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ark Therapeutics Ltd
Original Assignee
Eurogene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurogene Ltd filed Critical Eurogene Ltd
Priority to GBGB0012997.3A priority Critical patent/GB0012997D0/en
Publication of GB0012997D0 publication Critical patent/GB0012997D0/en
Priority to PL36028001A priority patent/PL360280A1/en
Priority to AU2001258657A priority patent/AU2001258657A1/en
Priority to KR1020027015961A priority patent/KR20030072213A/en
Priority to EP01931975A priority patent/EP1283894A1/en
Priority to CA002413326A priority patent/CA2413326A1/en
Priority to HU0302119A priority patent/HUP0302119A3/en
Priority to MXPA02011517A priority patent/MXPA02011517A/en
Priority to IL15307001A priority patent/IL153070A0/en
Priority to CN01810175A priority patent/CN1430675A/en
Priority to JP2001586586A priority patent/JP2003533992A/en
Priority to PCT/GB2001/002383 priority patent/WO2001090390A1/en
Priority to NO20025657A priority patent/NO20025657D0/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
GBGB0012997.3A 2000-05-26 2000-05-26 Gene delivery Ceased GB0012997D0 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
GBGB0012997.3A GB0012997D0 (en) 2000-05-26 2000-05-26 Gene delivery
PCT/GB2001/002383 WO2001090390A1 (en) 2000-05-26 2001-05-29 Use of baculovirus vectors in gene therapy
HU0302119A HUP0302119A3 (en) 2000-05-26 2001-05-29 Use of baculovirus vectors in gene therapy
AU2001258657A AU2001258657A1 (en) 2000-05-26 2001-05-29 Use of baculovirus vectors in gene therapy
KR1020027015961A KR20030072213A (en) 2000-05-26 2001-05-29 Use of baculovirus vectors in gene therapy
EP01931975A EP1283894A1 (en) 2000-05-26 2001-05-29 Use of baculovirus vectors in gene therapy
CA002413326A CA2413326A1 (en) 2000-05-26 2001-05-29 Use of baculovirus vectors in gene therapy
PL36028001A PL360280A1 (en) 2000-05-26 2001-05-29 Use of baculovirus vectors in gene therapy
MXPA02011517A MXPA02011517A (en) 2000-05-26 2001-05-29 Use of baculovirus vectors in gene therapy.
IL15307001A IL153070A0 (en) 2000-05-26 2001-05-29 Use of baculovirus vectors in gene therapy
CN01810175A CN1430675A (en) 2000-05-26 2001-05-29 Use of baculovirus vectors in gene therapy
JP2001586586A JP2003533992A (en) 2000-05-26 2001-05-29 Gene delivery by viral vector
NO20025657A NO20025657D0 (en) 2000-05-26 2002-11-25 Use of Baculovirus Vectors in Gene Therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0012997.3A GB0012997D0 (en) 2000-05-26 2000-05-26 Gene delivery

Publications (1)

Publication Number Publication Date
GB0012997D0 true GB0012997D0 (en) 2000-07-19

Family

ID=9892534

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0012997.3A Ceased GB0012997D0 (en) 2000-05-26 2000-05-26 Gene delivery

Country Status (13)

Country Link
EP (1) EP1283894A1 (en)
JP (1) JP2003533992A (en)
KR (1) KR20030072213A (en)
CN (1) CN1430675A (en)
AU (1) AU2001258657A1 (en)
CA (1) CA2413326A1 (en)
GB (1) GB0012997D0 (en)
HU (1) HUP0302119A3 (en)
IL (1) IL153070A0 (en)
MX (1) MXPA02011517A (en)
NO (1) NO20025657D0 (en)
PL (1) PL360280A1 (en)
WO (1) WO2001090390A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002096469A2 (en) * 2001-05-29 2002-12-05 Ark Therapeutics Ltd. Gene delivery via a baculovirus vector
SG135176A1 (en) 2004-02-02 2007-09-28 Ambrx Inc Modified human four helical bundle polypeptides and their uses
JP2008503217A (en) 2004-06-18 2008-02-07 アンブレツクス・インコーポレイテツド Novel antigen-binding polypeptides and their use
NZ584597A (en) 2004-12-22 2011-09-30 Ambrx Inc Modified human growth hormone
CA2590590C (en) 2004-12-22 2016-04-19 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
CN103520735B (en) 2004-12-22 2015-11-25 Ambrx公司 Comprise non-naturally encoded amino acid whose formulations of human growth hormone
SG161210A1 (en) 2004-12-22 2010-05-27 Ambrx Inc Methods for expression and purification of recombinant human growth hormone
WO2006068802A2 (en) 2004-12-22 2006-06-29 Ambrx, Inc. COMPOSITIONS OF AMINOACYL-tRNA SYNTHETASE AND USES THEREOF
CN103030690A (en) 2005-06-03 2013-04-10 Ambrx公司 Improved human interferon molecules and their uses
JP2009520949A (en) 2005-11-16 2009-05-28 アンブルックス，インコーポレイテッド Compositions and methods containing unnatural amino acids
DK2615108T3 (en) 2006-09-08 2017-01-30 Ambrx Inc Modified human plasma polypeptide or fc scaffolds and their applications
JP5451390B2 (en) 2006-09-08 2014-03-26 アンブルックス，インコーポレイテッド Transcription of suppressor TRNA in vertebrate cells
EP2068909B1 (en) 2007-03-30 2012-04-25 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
BRPI0810622A2 (en) 2007-05-02 2020-10-13 Ambrx, Inc. modified interferon beta polypeptides and their uses
KR101656107B1 (en) 2007-11-20 2016-09-08 암브룩스, 인코포레이티드 Modified insulin polypeptides and their uses
EP3103880A1 (en) 2008-02-08 2016-12-14 Ambrx, Inc. Modified leptin polypeptides and their uses
BRPI0916515B8 (en) 2008-07-23 2021-07-27 Ambrx Inc bovine granulocyte colony-stimulating factor polypeptide (bg-csf), pharmaceutical formulation and composition comprising the same
CN101358204B (en) * 2008-08-29 2011-05-18 浙江理工大学 Method for preparing cellular membrane and cellular organelle membrane protein after human enveloped virus budding
US8278418B2 (en) 2008-09-26 2012-10-02 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
NO2337846T3 (en) 2008-09-26 2018-06-16
MX2012006980A (en) 2009-12-21 2012-07-17 Ambrx Inc Modified porcine somatotropin polypeptides and their uses.
NZ600361A (en) 2009-12-21 2014-06-27 Ambrx Inc Modified bovine somatotropin polypeptides and their uses
JP6054294B2 (en) 2010-08-17 2016-12-27 アンブルックス, インコーポレイテッドAmbrx, Inc. Modified relaxin polypeptides and uses thereof
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
TWI480288B (en) 2010-09-23 2015-04-11 Lilly Co Eli Formulations for bovine granulocyte colony stimulating factor and variants thereof
LT3412302T (en) 2014-10-24 2021-07-26 Bristol-Myers Squibb Company Modified fgf-21 polypeptides and uses thereof
BR112019016139A2 (en) 2017-02-08 2020-04-07 Bristol-Myers Squibb Company modified relaxin polypeptide comprising a pharmacokinetic enhancer and uses thereof
CN114736929B (en) * 2022-05-16 2023-06-09 睿征医药科技(武汉)有限公司 Composition, method and application for producing recombinant baculovirus in insect cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU223957B1 (en) * 1996-11-01 2005-03-29 Eurogene Limited Therapeutic use of vegf protein or nucleic acid coding same and implant, especially for the treatment of intimal hyperplasia
DE19735593C2 (en) * 1997-08-15 1999-08-26 Hepavec Ag Fuer Gentherapie Coat protein-modified baculovirus vector for gene therapy
EP1100946A1 (en) * 1998-07-24 2001-05-23 Aventis Pharma S.A. Vectors derived from baculovirus and use for transferring nucleic acids into nerve cells of vertebrates

Also Published As

Publication number Publication date
KR20030072213A (en) 2003-09-13
MXPA02011517A (en) 2004-01-26
AU2001258657A1 (en) 2001-12-03
WO2001090390A1 (en) 2001-11-29
PL360280A1 (en) 2004-09-06
HUP0302119A3 (en) 2005-12-28
CA2413326A1 (en) 2001-11-29
JP2003533992A (en) 2003-11-18
HUP0302119A2 (en) 2003-09-29
IL153070A0 (en) 2003-06-24
NO20025657L (en) 2002-11-25
CN1430675A (en) 2003-07-16
WO2001090390A9 (en) 2003-01-09
NO20025657D0 (en) 2002-11-25
EP1283894A1 (en) 2003-02-19

Similar Documents

Publication Publication Date Title
GB0012997D0 (en) Gene delivery
GB0019745D0 (en) Gene expression element
HUP0105208A3 (en) Gene therapy-1
GB0007651D0 (en) Gene sequence
AU6424701A (en) Gasc1 gene
IL146332A0 (en) PrP-LIKE GENE
GB0122232D0 (en) Gene expression
GB2362383B (en) Gene expression system
GB0014898D0 (en) Delivery system
EP1215284A4 (en) Tsg-like gene
GB2361643B (en) Delivery capsules
EP1387892A4 (en) Gene delivery compounds
GB0011938D0 (en) Improvements relating to gene delivery systems
GB9916699D0 (en) Gene delivery
GB0026892D0 (en) Nucleic acid delivery
GB0028570D0 (en) Bacterial gene
GB0113857D0 (en) Delivery system
GB0000213D0 (en) Delivery assemblage
GB0016912D0 (en) Delivery assemblage
GB0029357D0 (en) Tolerance gene
GB0125208D0 (en) Delivery form
GB0001935D0 (en) Delivery system
GB0026332D0 (en) Delivery system
GB0005844D0 (en) Gene therapy
GB0005846D0 (en) Gene therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)